FASCE: The Benefit of Spironolactone for Treating Acne in Women - Study Protocol for a Randomized Double-Blind Trial

    June 2020 in “ Trials
    Alexandra Poinas, M Lemoigne, S. Le Naour, Jean–Michel Nguyen, Solène Schirr-Bonnans, Valéry-Pierre Riche, Florence Vrignaud, L. Machet, Jean‐Paul Claudel, Marie‐Thérèse Leccia, E. Hainaut, N. Bénéton, Cécile Dert, Aurélie Boisrobert, Laurent Flet, Anne Chiffoleau, Stéphane Corvec, Amir Khammari, Brigitte Dréno
    New to Spironolactone? There is a guide in the encyclopedia. Read the guide →
    Studysummary This study aims to conduct the first double-blind randomized trial comparing spironolactone and doxycycline for female acne treatment, with the goal of establishing spironolactone as a potentially superior alternative, especially given concerns about antibiotic resistance.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →

    Research cited in this study

    5 / 5 results